Literature DB >> 28392912

Erratum to: Looking forward to new targeted treatments for chronic spontaneous urticaria.

Emek Kocatürk¹, Marcus Maurer², Martin Metz², Clive Grattan³.

Abstract

[This corrects the article DOI: 10.1186/s13601-016-0139-2.].

Entities: Chemical Disease

Year: 2017 PMID： 28392912 PMCID： PMC5376682 DOI： 10.1186/s13601-017-0148-9

Source DB: PubMed Journal: Clin Transl Allergy ISSN： 2045-7022 Impact factor: 5.871

Erratum to: Clin Transl Allergy (2017) 7:1 DOI 10.1186/s13601-016-0139-2

Information from the manufacturer of the topical intervention in the GSK2646264 trial outlined in this review [1] indicates that the half-life of the product has not been established with certainty on the available data.

1 in total

Review 1. Looking forward to new targeted treatments for chronic spontaneous urticaria.

Authors: Emek Kocatürk; Marcus Maurer; Martin Metz; Clive Grattan
Journal: Clin Transl Allergy Date: 2017-01-10 Impact factor: 5.871

1 in total